The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 11, 2016
Filed:
Sep. 24, 2014
The United States of America, As Represented BY the Secretary of Agriculture, Washington, DC (US);
The University of Connecticut, Storrs, CT (US);
Manuel V. Borca, Westbrook, CT (US);
Lauren G. Holinka-Patterson, Deep River, CT (US);
Douglas Gladue, Guildford, CT (US);
Guillermo R. Risatti, Westbrook, CT (US);
Vivian K. O'Donnell, Old Saybrook, CT (US);
The United States of America, as represented by the Secretary of Agriculture, Washington, DC (US);
University of Connecticut, Farmington, CT (US);
Abstract
African swine fever virus (ASFV) is the etiological agent of a contagious and often lethal viral disease of domestic pigs that has significant economic consequences for swine breeding. Control of ASF has been hampered by the unavailability of vaccines. Recombinant viruses harboring engineered deletions of specific virulence-associated genes induce solid protection against the challenge with parental viruses. Here we report the construction of a recombinant Δ9GL virus derived from the highly virulent ASFV Georgia 2007 (ASFV-G) isolate. In vivo, ASFV-G Δ9GL administered intramuscularly (IM) to swine at relatively high doses (10HAD) retains a virulent phenotype practically indistinguishable from the parental virus. Conversely, at low IM doses (10or 10HAD), ASFV-G Δ9GL does not induce disease. Importantly, animals infected with 10HADare protected against the presentation of clinical disease when challenge at 28 days post infection with the virulent parental strain Georgia 2007.